A common asthma medication used for decades is now drawing attention in cancer research after scientists found it may help the immune system fight some of the hardest cancers to treat. Researchers studying montelukast, a drug widely prescribed for asthma and allergies, say the medication showed encouraging results against aggressive tumors in early laboratory and animal studies.
Why Researchers Are Exploring Asthma Drug Cancer Treatment
Montelukast has long been used to reduce inflammation in people with asthma and allergies. The medication works by blocking leukotrienes, chemicals in the body that trigger inflammation and airway constriction.
Cancer researchers recently discovered that tumors may also use these same inflammatory pathways to weaken immune responses. According to the early study highlighted by Live Science, scientists found that certain cancer cells rely on a receptor called CysLTR1 to create an environment that protects tumors from immune attacks.
By blocking this receptor with montelukast, researchers observed signs that immune cells became more active against tumors. This raised the possibility that the drug could improve how the immune system responds to difficult cancers.
The study mainly focused on aggressive cancers that often resist standard therapies, including triple-negative breast cancer. Researchers also believe the approach may help some patients who do not respond well to immunotherapy.
A separate report from Northwestern University explained that the drug appeared to interfere with the way tumors communicate with immune cells, potentially reducing the cancer's ability to hide from the immune system.
Why Triple-Negative Breast Cancer Is So Difficult to Treat
Triple-negative breast cancer is considered one of the most aggressive forms of breast cancer because it lacks three common receptors often targeted by treatment:
- Estrogen receptors
- Progesterone receptors
- HER2 proteins
Many breast cancer therapies work by targeting one of these receptors. Since triple-negative tumors do not contain them, treatment options are more limited. Doctors often rely on chemotherapy, surgery, radiation, and immunotherapy, but outcomes can still vary widely. Some tumors quickly develop resistance to treatment, making recurrence more likely.
Several factors make triple-negative breast cancer especially challenging:
- Faster tumor growth
- Higher risk of spreading to other organs
- Greater recurrence rates during the first few years
- Limited targeted treatment options
Researchers have spent years trying to identify new ways to weaken these tumors. The latest Montelukast cancer research may offer another potential strategy by targeting inflammation and immune suppression instead of hormone pathways.
How the Asthma Drug Helped in Early Cancer Research
In the recent study, researchers tested montelukast in preclinical cancer models. They found that blocking leukotriene signaling appeared to slow tumor growth and improve immune activity around the cancer.
Scientists observed that tumors often recruit immune cells called neutrophils in ways that help cancer survive. Instead of attacking the tumor, these cells can sometimes suppress immune responses and create a protective environment for cancer cells.
Montelukast appeared to disrupt part of this process.
Researchers believe the treatment may help "reprogram" the tumor environment, allowing immune cells to function more effectively. This could become particularly important for immunotherapy resistant cancers that stop responding to checkpoint inhibitor drugs.
According to EurekAlert, scientists also saw signs that combining the asthma medication with immunotherapy may improve treatment responses in some cancers. Although the results are still preliminary, researchers say the findings reveal how inflammation pathways can influence tumor survival.
Why Drug Repurposing Is Becoming More Common in Cancer Research
Developing new cancer drugs can take more than a decade and cost billions of dollars. Drug repurposing offers a faster alternative because the medications already exist and have known safety records. Researchers see several advantages to repurposing drugs like montelukast:
- Existing safety and dosage information
- Lower research and development costs
- Faster transition into clinical trials
- Potentially broader patient access if approved
This approach has already produced important treatments in medicine. Some drugs originally designed for diabetes, blood pressure, and infections have later shown anti-cancer properties.
Montelukast cancer research fits into this broader effort to identify overlooked medications that may affect cancer biology in unexpected ways.
Scientists say inflammatory signaling pathways are becoming a major focus because they influence both tumor growth and immune activity.
Read Also: Multiple Sclerosis Fitness: Safe Cardio, Strength, and Neuro Rehab Exercises for Fatigue Management
Could Montelukast Improve Immunotherapy?
Immunotherapy has transformed cancer treatment over the past decade, especially for cancers like melanoma and lung cancer. These therapies help the immune system recognize and attack cancer cells more effectively.
However, not all patients respond to immunotherapy. Some cancers develop resistance mechanisms that weaken immune responses or block immune cells from entering tumors.
This is one reason immunotherapy resistant cancers remain a major challenge in oncology.
Researchers believe montelukast may help by reducing inflammation-related immune suppression inside tumors. If future studies confirm the findings, the drug could potentially:
- Improve checkpoint inhibitor responses
- Enhance immune cell activity
- Reduce tumor resistance mechanisms
- Support combination cancer therapies
Scientists caution that much more testing is needed before these ideas can be confirmed in human patients.
Important Risks and Limitations Researchers Still Need to Study
Despite the excitement surrounding the findings, experts emphasize that the research is still in an early phase.
Most of the current data comes from laboratory and animal studies, not large human clinical trials. Many treatments that appear promising in mice fail to show the same success in people.
Researchers also need to determine:
- Which cancers respond best
- What dosage levels are safe for cancer treatment
- Whether the drug works alone or only in combination therapies
- Which patients may benefit most
Montelukast also carries known side effects. The U.S. Food and Drug Administration previously added warnings about possible mental health side effects, including mood changes and sleep disturbances in some patients. For that reason, experts strongly advise against self-treatment outside clinical supervision.
What Researchers Hope Happens Next
Scientists are now pushing for human clinical trials involving montelukast and aggressive cancers. Researchers are especially interested in combining the drug with existing immunotherapy treatments to see whether it improves response rates.
Future studies may focus on:
- Triple-negative breast cancer
- Lung cancer
- Pancreatic cancer
- Other immunotherapy resistant cancers
If larger studies confirm the early findings, the asthma drug cancer treatment approach could become part of a broader strategy for helping patients whose cancers do not respond well to current therapies.
Frequently Asked Questions
1. Can asthma medication really help treat cancer?
Researchers believe some asthma drugs affect inflammation and immune pathways that tumors also use to survive. Early studies suggest montelukast may help improve immune responses against certain aggressive cancers.
2. What is triple-negative breast cancer?
Triple-negative breast cancer is a type of breast cancer that lacks estrogen, progesterone, and HER2 receptors. Because it does not respond to many targeted therapies, it is often harder to treat.
3. Is montelukast approved for cancer treatment?
No. Montelukast is currently approved for asthma and allergy treatment. Its use in cancer therapy is still experimental and being studied in early research.
4. Why are researchers interested in drug repurposing?
Repurposing existing medications can reduce development costs and speed up testing because the drugs already have known safety records and manufacturing systems in place.